Lilly Bracing For Possible Medicare Non-Coverage Or CED Decision On Amyvid
This article was originally published in The Pink Sheet Daily
Lilly executives discuss likely outcomes of a pending CMS draft decision on Medicare coverage for the beta amyloid imaging agent Amyvid, emphasizing that a decision for non-coverage or coverage with evidence development would be a major setback for research and development in Alzheimer’s disease.
You may also be interested in...
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.